Last Updated: November 13, 2026

Litigation Details for Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)

« Back to Dashboard


Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)

Docket 1:15-cv-00272-GMS Date Filed 2015-03-27
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Patents 7,834,020; 8,193,195; 8,236,804; 8,673,921
Link to Docket External link to docket
Small Molecule Drugs cited in Forest Laboratories LLC v. Accord Healthcare Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Details for Forest Laboratories LLC v. Accord Healthcare Inc. (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-03-27 105 .S. Patent Nos. 7,834,020 ("the '020 patent"), 8,193,195 ("the '195 patent"…that because claim 1 of U.S. Patent No. 7,834,020, claim 1 of U.S. Patent No. 8,236,804, and claims 5,… ORDER CONSTRUING THE TERMS of U.S. Patent Nos. 7,834,020, 8,193,195, 8,236,804, and 8,673,921. Signed…CONSTRUING THE TERMS OF U.S. PATENT NOS. 7,834,020, 8,193,195, 8,236,804, AND 8,673,921 …in the patent. '020 patent, col. 27 ll.42-43; '804 patent, col. 28, 1. 1; '921 patent, col. External link to document
2015-03-27 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,834,020; 8,193,195; 8,236,804… 27 March 2015 1:15-cv-00272-GMS Patent None District Court, D. Delaware External link to document
2015-03-27 86 other disorders. The patents-in-suit are U.S. Patent Nos. 7,834,020 (the “ ’020 patent”), 8,193,195 (the…the “ ’195 patent”), 8,236,804 (the “ ’804 patent”), and 8,673,921 (the “ ’921 patent”). While Forest … the ’020 patent, claim 1 of the ’804 patent, and claims 5, 11, and 13 of the ’921 patent, “crystalline…admits that a prior art patent, U.S. Patent No. 5,532,241 (the “ ’241 patent”), discloses vilazodone …804 Patent. The PTO rejected claim 1 of the ’804 patent as anticipated by the ’241 patent. See External link to document
2015-03-27 87 licensee of U.S. Patent Nos. 7,834,020 (“the ’020 patent”); 8,193,195 (“the ’195 patent”); 8,236,804 (“…(“the ’804 patent”); and 8,673,921 (“the ’921 patent”) (collectively, “the patents-in-suit”), which are… U.S. Patent No. 5,532,241 (“’241 patent”), which is incorporated by reference in the patents-in- …Merck Patent Gesellschaft mit beschränkter Haftung (collectively, “Merck”). The patents-in-suit…including major 1 The patents-in-suit all claim priority to a June 2001 patent application. External link to document
2015-03-27 88 infringed U.S. Patent Nos. 7,834,020 (the “’020 patent”), 8,193,195 (the “’195 patent”), 8,236,804 (the…22/16 Page 2 of 18 PageID #: 768 patent”) (collectively, “patents-in-suit”), by filing Abbreviated New… not present. VII. THE PATENTS-IN-SUIT 27. The patents-in-suit describe the invention…., ‘804 patent, col. 2, l. 39 to col. 3, l. 30; col. 5, ll. 1-22. Additionally, during patent prosecution…Ltd., Forest Laboratories LLC, Merck KGaA, Merck Patent Gesellschaft mit beschrankter Haftung. (Attachments External link to document
2015-03-27 93 drug Viibryd®. The patents-in-suit are U.S. Patent Nos. 7,834,020 (the “ ’020 patent”), 8,193,195 (the…the “ ’195 patent”), 8,236,804 (the “ ’804 patent”), and 8,673,921 (the “ ’921 patent”), which all relate…administering” ’804 patent, claim 1 ’921 patent, claims 10, 12- …07/27/16 Page 13 of 27 PageID #: 1000 patent – U.S. Patent No. 5,532,241 of Bottcher et al. (“Bottcher…of the ’094 Patent. Id. at *14-15. In this case, each of the patents-in-suit is titled External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.